15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings, in CNY as reported — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | CN¥454M | -CN¥93M | 5.7% | -57.6% | 4.4% | -1.4% | -CN¥258M | CN¥3.4B | CN¥298M |
| 2024 | CN¥375M | -CN¥308M | -21.1% | -142.1% | 13.5% | -4.6% | -CN¥549M | CN¥3.7B | CN¥216M |
| 2023 | CN¥521M | -CN¥298M | -14.7% | -88.9% | 14.0% | -4.9% | -CN¥389M | CN¥3.0B | CN¥58M |
| 2022 | CN¥450M | -CN¥490M | -33.9% | -116.6% | 26.3% | -8.2% | -CN¥440M | CN¥3.0B | CN¥158M |
| 2021 | CN¥443M | -CN¥271M | -12.8% | -103.4% | 19.8% | -4.4% | -CN¥638M | CN¥2.5B | CN¥157M |
| 2020 | CN¥170M | -CN¥310M | 7.7% | -185.8% | 46.8% | -5.8% | -CN¥398M | CN¥2.1B | CN¥334M |
| 2019 | CN¥140M | -CN¥307M | -11.3% | -312.8% | 250.1% | -7.1% | -CN¥428M | CN¥1.6B | CN¥74M |
| 2018 | CN¥114M | -CN¥235M | 17.3% | -262.1% | -53.7% | -5.1% | -CN¥204M | CN¥938M | CN¥405M |
| 2017 | CN¥91M | -CN¥284M | 107.2% | -231.8% | -30.4% | -8.2% | -CN¥65M | CN¥994M | CN¥98M |
| 2016 | CN¥455M | -CN¥262M | 37.0% | -37.1% | -22.5% | -8.1% | -CN¥157M | CN¥861M | CN¥190M |
| 2015 | — | -CN¥78M | — | — | -5.6% | -2.2% | -CN¥223M | CN¥1.2B | — |
| 2014 | — | CN¥125M | — | — | 6.9% | 4.2% | CN¥439M | CN¥904M | — |
| 2013 | — | CN¥86M | — | — | 4.0% | 2.1% | CN¥184M | CN¥1.1B | — |
| 2012 | — | CN¥131M | — | — | 6.4% | 3.6% | CN¥194M | CN¥875M | — |
| 2011 | — | -CN¥215M | — | — | -11.1% | -9.0% | CN¥119M | CN¥201M | — |
Over the past 5 years, Concord Medical Services Holdings Ltd's revenue has grown 21.7% per year. These are computed facts, not advice.
As of FY2025, Concord Medical Services Holdings Ltd reported CN¥3.4B of total debt against CN¥298M of cash; operating income covered interest expense -1.7×.
In FY2025, gross margin was 5.7%, operating margin -57.6%, and net margin -20.4%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — its annual and interim reports, in CNY as reported (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (annual and interim filings, reported in CNY) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.